Multiple Myeloma

The past decade has witnessed dramatic progress in the treatment of multiple myeloma (MM), which has resulted in unprecedented improvements in survival outcomes.

Recent advancements in the treatment of multiple myeloma (MM) have led to significant improvements in patient outcomes, including unprecedented survival rates. Such progress has allowed a paradigm shift toward a chronic care model, with attention increasingly focused on improving patients’ quality of life.

Oral oncolytics offer the ease of self-administration to patients. There is no prodding for stubborn veins, and no need for a port. Therefore, oral therapies empower patients, and often lead to improved quality of life.